Companiesandmarkets.com: Commercial Biotechnology Separation Systems Market to See Increased Demand from Emerging Markets

LONDON--(BUSINESS WIRE)-- Over the next five years the biomolecule separation market will experience considerable growth, according to a new report available from companiesandmarkets.com. This market expansion is being attributed to new developments within the separation technology market, as well as increased interest from Japan and other countries within the Pacific Rim.

Separation Systems for Commercial Biotechnology

http://www.companiesandmarkets.com/Market-Report/separation-systems-for-commercial-biotechnology-695380.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

The market for separation systems – biomolecule and protein techniques – is expanding, with protein separation technologies in particular taking on an increasingly influential role within biopharmaceutical R&D.

Important end users of biotechnology separation systems include the following industries: pharmaceuticals; food, cosmetics, and agriculture; and energy.

This separation systems research report investigates the separations systems market by examining the proteins which can be deployed as biotherapeutic agents to fight against disease. It discusses those products which gained FDA approval during 2009 and 2010, as well as those which are likely to be approved by 2016, and explains the separation technologies which they will require.

The commercial biomolecular separation market report considers the following products, amongst others: proteins, antibodies, enzymes, nucleic acids, hormones, cells, blood and serum products, and organic products.

A number of industry participants are profiled within the separation systems for commercial biotechnology research report, including: Affymetrix, Alfa Laval Group, Applied Biosystems Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Caliper Life Sciences, Dionex, GE Healthcare Life Sciences, Invitrogen, Life Technologies, Pall Corporation, Perkin-Elmer, Qiagen GmbH, Sepmag Technologies, Shimadzu Scientific Instruments, Tecan Group, Ltd., Thermo Fisher Scientific, Waters Corporation and Whatman International, Ltd.

The September 2011 research piece includes 129 pages of insight into the commercial biotechnology separation systems market, including historical and forecast statistics for the period 2010-2016. The market is split by product, by geography and by company, and includes in-depth discussion around industry participants, strategies, patents, trends, opportunities, barriers/drivers, amongst other aspects.

The report will be of interest to those actively working with biomolecule separation technologies, or those evaluating opportunities within the pharmaceutical and biotechnology markets.

Report Details:

http://www.companiesandmarkets.com/Market-Report/separation-systems-for-commercial-biotechnology-695380.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Companies & Markets
Mike King
Press Office
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.